ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alto Neuroscience Inc (ANRO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive signals from technical analysis, trading sentiment, and financial performance. While analysts have raised price targets, the company's financials remain weak, and there are no significant catalysts or influential trading activity to support a strong buy recommendation. A hold position is more appropriate until more favorable conditions arise.
The MACD histogram is negative (-0.362) and contracting, RSI is neutral at 44.948, and moving averages are converging. The stock is trading below the pivot level of 22.082, with key support at 19.883 and resistance at 24.282. These indicators suggest a lack of clear upward momentum.
The company's focus on precision psychiatry and ongoing trials may yield long-term benefits.
Hedge funds are selling heavily, with a 159.20% increase in selling activity last quarter. Financial performance is weak, with no revenue growth, a net income loss of -$16.18M, and a declining EPS (-17.54% YoY). No recent news or significant trading activity from insiders or Congress.
In Q4 2025, revenue remained at $0 with no growth. Net income improved slightly (-6.45% YoY), but EPS dropped by -17.54%. The company remains unprofitable, and gross margins are non-existent.
Analysts are cautiously optimistic, with Baird and BTIG maintaining positive ratings and raising price targets. However, Wedbush remains neutral, highlighting the company's financial challenges despite its extended cash runway and ongoing trials.
